Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.
Brittany Lovely
Advertisement
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies.
Articles by Brittany Lovely
Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
ASCO 2023: Solid TumorsPublished: July 31st 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
2
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
3
New Biomarkers, Drug Targets Identified for Colorectal Cancer
4
Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations
5
